Login to Your Account

Clinic Roundup

Wednesday, September 21, 2011
Santarus Inc., of San Diego, said analysis of top-line safety data from a 12-month extended-use study in patients treated daily with either budesonide MMX 6 mg or placebo showed a similar frequency of treatment-related adverse events for both groups (21 percent to 21.3 percent) and no clinically meaningful differences in the numbers of patients with abnormal bone mineral density scans at baseline and end of the study between the budesonide and placebo groups.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription